Liver Cancer

Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious side effects leading to regorafenib treatment discontinuation, researchers have found.

Keytrida plus Lenvima improved survival and duration of response in patients with advanced hepatocellular carcinoma.

Antiviral treatments play a crucial role in the survival of patients with either hepatitis B or C and liver cancer, but researchers have found that antiviral therapy is “severely underutilized” even among patients who undergo curative surgery.

In honor of Liver Cancer Awareness Month, CURE® highlighted some of the most impactful liver cancer developments from 2023.

Tislelizumab demonstrated similar overall survival and safety in unresectable hepatocellular carcinoma compared with Nexavar, research found.

Adding TPST-1120 to the standard of care for the treatment of unresectable or metastatic hepatocellular carcinoma, a type of liver cancer, improved progression-free survival and overall survival in a phase 1b/2 clinical study.

Using antidepressants after receiving a diagnosis of liver cancer may lower overall and cancer-specific mortality rates, according to recent research.

Rivoceranib plus Airuika demonstrates improvement for survival in patients with unresectable hepatocellular carcinoma, a subset of liver cancer.

Patients with unresectable hepatocellular carcinoma, a type of liver cancer, obtained a survival benefit over four years of follow-up with a treatment regimen of Imfinzi and Imjudo.

Treatment with a CAR-M cell therapy plus Keytruda is being assessed in a phase 1 study in patients with HER2-overexpressed tumors.

Patients with unresectable hepatocellular carcinoma treated with the STRIDE regimen, consisting of Imjudo and Imfinzi, experienced manageable immune-related side effects with improvements in overall survival.

Patients born outside of the U.S. may have improved liver cancer survival rates compared with U.S.-born patients, although more research is needed to determine what may be driving this effect, research showed.

TPST-1120 is displaying potential in combatting hepatocellular carcinoma, the fastest-rising cause of cancer-related death in the United States.

The use of ChatGPT (an artificial intelligence platform) tended to produce reliable cancer-related information in most circumstances, but patient-provider communication is still key, an expert said.

Patients with type 2 diabetes have an increased cancer burden and, as a result, a higher mortality rate, highlighting the importance of inflammatory factors like obesity and glucose control.

Patients with advanced HCC who progressed after treatment with immunotherapy may have a survival benefit when treated with second-line Lenvima.

Good science, along with creativity in applying and testing it properly, can be successful against all odds for patients with cholangiocarcinoma.

If approved by the FDA, zanidatamab could be the first HER-2 targeted therapy for patients with biliary tract cancers.

Biliary duct cancer, or cholangiocarcinoma, has always been known as a difficult-to-treat disease, but immunotherapies may make an impact on patients' lives.

After Marshall Morris was diagnosed with a rare cancer and given only six months to live, he created a charity that empowers people with terminal illness and provides them with counseling and support.

The FDA approved Imjudo plus Imfinzi for advanced hepatocellular carcinoma, although more work is needed to develop a treatment that cures patients, an expert said.

The dual immunotherapy regimen of Imjudo and Imfinzi may provide patients with unresectable hepatocellular carcinoma a well-tolerated treatment to extend survival.

The Food and Drug Administration approved Imfinzi plus gemcitabine and cisplatin for locally advanced or metastatic biliary tract cancer.

From “EastEnders” star Samantha Womack announcing her breast cancer diagnosis in a tribute to Olivia Newton-John to a famous fashion designer’s death from liver cancer, here’s what’s happening in the oncology space this week.

Treatment with Keytruda plus Lenvima did not best Lenvima alone as a first-line treatment option for a group of patients with liver cancer that could not be treated with surgery, according to recently announced study results from a phase 3 clinical trial.